Holen Sie sich die Stockscreener-App
7.23
3.08%
-0.23
Handel nachbörslich:
7.03
-0.20
-2.77%
Schlusskurs vom Vortag:
$7.46
Offen:
$7.44
24-Stunden-Volumen:
283.56K
Relative Volume:
1.70
Marktkapitalisierung:
$415.67M
Einnahmen:
$154.57M
Nettoeinkommen (Verlust:
$15.07M
KGV:
26.78
EPS:
0.27
Netto-Cashflow:
$10.92M
1W Leistung:
-7.13%
1M Leistung:
+0.56%
6M Leistung:
+26.40%
1J Leistung:
+17.56%
1-Tages-Spanne:
$7.07
$7.4604
1-Wochen-Bereich:
$7.07
$8.02
52-Wochen-Spanne:
$4.74
$9.155
Kamada Ltd Stock (KMDA) Company Profile
Vergleichen Sie KMDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.23 | 415.67M | 154.57M | 15.07M | 10.92M | 0.27 |
|
ZTS
Zoetis Inc
|
165.31 | 74.02B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.15 | 45.90B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.08 | 44.64B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.23B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.57 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-03 | Eingeleitet | Stifel | Buy |
| 2018-02-02 | Eingeleitet | Chardan Capital Markets | Buy |
Kamada Ltd Aktie (KMDA) Neueste Nachrichten
Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET - The Manila Times
Alvotech heldur kynningarfund fyrir fjárfesta 27. mars 2025, eftir birtingu uppgjörs fyrir árið 2024 og fjórða ársfjórðung - GlobeNewswire Inc.
Alpha-1 Protease Inhibitor Deficiency Therapeutics Market - openPR
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - Finansavisen
Kamada Ltd. (NASDAQ:KMDA) Short Interest Down 81.5% in January - MarketBeat
Kamada (NASDAQ:KMDA) Sets New 1-Year HighHere's Why - MarketBeat
Kamada (NASDAQ:KMDA) Reaches New 12-Month HighStill a Buy? - MarketBeat
Alpha-1 Antitrypsin Deficiency Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight - The Globe and Mail
Potential Price Increase for Kamada Ltd (KMDA) After Recent Insider Activity - Knox Daily
The Potential Rise in the Price of Vivid Seats Inc (SEAT) following insiders activity - Knox Daily
Kamada Ltd’s Mixed Bag: Up 45.64% in 6 Months, Up 13.09% in 30 Days - The InvestChronicle
Red Cat Holdings Inc (RCAT) Shares Soar Above 1-Year High - The News Heater
Kamada Ltd (KMDA) Shares Rise Despite Market Challenges - The News Heater
Y.D. More Investments Ltd Reduces Stock Holdings in Kamada Ltd. (NASDAQ:KMDA) - MarketBeat
Short Interest in Kamada Ltd. (NASDAQ:KMDA) Expands By 33.3% - MarketBeat
High Growth Tech Stocks To Watch In January 2025 - Simply Wall St
Kamada to supply immune globulin products in Latin America - Pharmaceutical Business Review
Kamada secures $25 million Latin America contract - MSN
Kamada Secures $25 Million Contract for Immune Globulin Products in Latin America - TipRanks
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America - The Manila Times
Kamada Secures Major $25M Contract for Life-Saving Immunoglobulin Drugs in Latin America - StockTitan
Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 33.3% in December - MarketBeat
Kamada’s (KMDA) Buy Rating Reiterated at HC Wainwright - Defense World
Market Participants Recognise Kamada Ltd.'s (TLV:KMDA) Earnings Pushing Shares 25% Higher - Simply Wall St
Kamada's (KMDA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Kamada Projects Double-Digit Growth for 2025, Expands Plasma Operations - Yahoo Finance
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025 - GlobeNewswire
KMDA stock touches 52-week high at $6.53 amid market optimism By Investing.com - Investing.com South Africa
Kamada (NASDAQ:KMDA) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Comparing Endonovo Therapeutics (OTCMKTS:ENDVD) & Kamada (NASDAQ:KMDA) - Defense World
KMDA stock touches 52-week high at $6.53 amid market optimism - Investing.com Australia
Financial Survey: Kamada (NASDAQ:KMDA) versus Endonovo Therapeutics (OTCMKTS:ENDVD) - Defense World
Exploring High Growth Tech Stocks This January 2025 - Yahoo Finance
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - The Manila Times
Exploring Undiscovered Gems with Potential This December 2024 - Simply Wall St
So who replaces Eberechi Eze against Arsenal? Crystal Palace boss asked if summer signing will step in - South London News
Music Industry Moves: Avex USA Names Ryusuke Kamada CFO - Yahoo Entertainment
Kamada Ltd. Approves Board Re-Elections and Auditor Appointment - TipRanks
Finanzdaten der Kamada Ltd-Aktie (KMDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.92%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):